We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+6.48%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.13B
AUM Growth
+$1.04B
(+96%)
Cap. Flow
+$940M
Cap. Flow
% of AUM
44.08%
Top 10 Holdings %
Top 10 Hldgs %
46.5%
Holding
110
New
45
Increased
37
Reduced
1
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$98.6M |
| 2 |
Gilead Sciences
GILD
|
+$96.5M |
| 3 |
Pfizer
PFE
|
+$46.4M |
| 4 |
Johnson & Johnson
JNJ
|
+$33.9M |
| 5 |
AbbVie
ABBV
|
+$26.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FRX
FOREST LABORATORIES INC
FRX
|
+$10.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$2.11M |
| 3 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$1K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.82% |
| 2 | Real Estate | 2.39% |
| 3 | Financials | 1.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BDSI
51
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $8.57M | 0.4% |
501,553
| – | – |
|
|
DHC
52
Diversified Healthcare Trust
DHC
$2.17B
| $8.57M | 0.4% |
+413,190
| New | +$9.36M |
|
53
Community Health Systems
CYH
$391M
| $8.47M | 0.4% |
+187,153
| New | +$7.78M |
|
54
Ventas
VTR
$44.7B
| $8.45M | 0.4% |
+119,430
| New | +$8.72M |
|
55
Sabra Healthcare REIT
SBRA
$5.38B
| $8.35M | 0.39% |
+343,390
| New | +$9.52M |
|
56
HCA Healthcare
HCA
$85.7B
| $8.16M | 0.38% |
+115,688
| New | +$7.65M |
|
|
SGMO
57
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $8.09M | 0.38% |
750,100
+629,700
| +523% | +$8.22M |
|
58
Zimmer Biomet
ZBH
$18.4B
| $8.02M | 0.38% |
+82,194
| New | +$8.08M |
|
59
Stryker
SYK
$133B
| $7.74M | 0.36% |
+95,840
| New | +$7.88M |
|
|
MPT
60
Medical Properties Trust
MPT
$2.81B
| $7.69M | 0.36% |
+627,274
| New | +$8.34M |
|
|
IPXL
61
CALL
DELISTED
Impax Laboratories, Inc.
IPXL
| $7.65M | 0.36% |
+322,600
| New | +$8.26M |
|
|
STJ
62
DELISTED
St Jude Medical
STJ
| $7.37M | 0.35% |
+122,510
| New | +$8M |
|
63
CALL
Sarepta Therapeutics
SRPT
$1.64B
| $7.29M | 0.34% |
+345,400
| New | +$7.8M |
|
|
64
Sarepta Therapeutics
SRPT
$1.64B
| $7.29M | 0.34% |
+345,400
| New | +$7.8M |
|
65
Heron Therapeutics
HRTX
$94.1M
| $7.28M | 0.34% |
873,940
| – | – |
|
66
Revvity
RVTY
$12.7B
| $7.22M | 0.34% |
165,495
| – | – |
|
67
UnitedHealth
UNH
$383B
| $7.17M | 0.34% |
83,186
| – | – |
|
68
Idexx Laboratories
IDXX
$44.1B
| $6.63M | 0.31% |
112,530
| – | – |
|
69
CALL
Celldex Therapeutics
CLDX
$3.02B
| $6.59M | 0.31% |
+33,893
| New | +$7.38M |
|
|
70
Celldex Therapeutics
CLDX
$3.02B
| $6.59M | 0.31% |
+33,893
| New | +$7.38M |
|
|
NPSP
71
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $6.21M | 0.29% |
238,900
+156,000
| +188% | +$4.48M |
|
|
BLUE
72
DELISTED
bluebird bio
BLUE
| $6.21M | 0.29% |
13,350
+9,141
| +217% | +$4.22M |
|
|
AMRN
73
Amarin Corp
AMRN
$298M
| $6.15M | 0.29% |
282,171
+231,921
| +462% | +$7.55M |
|
|
ELGX
74
DELISTED
Endologix Inc
ELGX
| $5.84M | 0.27% |
+55,100
| New | +$7.68M |
|
|
WCG
75
DELISTED
Wellcare Health Plans, Inc.
WCG
| $5.35M | 0.25% |
+88,652
| New | +$5.88M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q3 2014 Portfolio in Review
As of Q3 2014, Tekla Capital Management held 110 positions worth $2.13B, up 96% from $1.09B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Tekla Capital Management deployed $940M of net new capital in Q3 2014, opening 45 new positions and adding to 37 existing holdings. Its largest new stake was Johnson & Johnson: 327,212 shares worth $34.9M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 89% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $2.11M trimmed.
- Tekla Capital Management's largest Q3 2014 buy was Johnson & Johnson: 327,212 shares worth $34.9M.
- Tekla Capital Management added most to Celgene Corp in Q3 2014, an estimated $98.6M increase.
- Tekla Capital Management's biggest Q3 2014 reduction was Regeneron Pharmaceuticals, cutting an estimated $2.11M.
- Tekla Capital Management fully exited FOREST LABORATORIES INC in Q3 2014, selling an estimated $10.9M.
- Tekla Capital Management's ten largest holdings make up 47% of its $2.13B portfolio in Q3 2014.
- Tekla Capital Management opened 45 new positions and closed 2 in Q3 2014.
- Tekla Capital Management's portfolio value rose 96% quarter-over-quarter to $2.13B.
Based on Tekla Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.